在BRAF ex15 p.T599dup突变驱动NSCLC中的BRAF/MEK向治疗:一个病例报告
Lan Jiang1, Pirong Yang1, Yufeng Liu1
1Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Centre, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China.
用达布拉费尼布加上特拉美丁尼布的向治疗对非小细胞肺癌 (NSCLC) 患者具有罕见的BRAF非V600E突变具有有希望. 这份病例报告强调了一个患有BRAF ex15 p.T599dup突变的患者的积极反应.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 在非小细胞肺癌 (NSCLC) 的1-5%中发生BRAF突变.
- BRAF V600E突变可以用达布拉芬尼 + 特拉美丁尼治疗.
- 非V600E BRAF突变是多样化的,对向治疗的临床数据有限.
更多相关视频
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
